Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside

Author(s): Z. Liu, F. Wang

Journal Name: Current Molecular Medicine

Volume 13 , Issue 10 , 2013

Become EABM
Become Reviewer
Call for Editor


The cell adhesion molecule integrin αvβ3 is an important player in the process of angiogenesis. In the last decades, a series of radiolabeled Arg-Gly-Asp (RGD) peptides targeting integrin αvβ3 has been prepared and optimized for positron emission tomography (PET) and single-photon-emission computed tomography (SPECT) imaging of integrin αvβ3 expression. Several promising radiotracers have been tested in clinical trials. In this review, we will introduce strategies that have been used to optimize and accelerate RGD radiotracers towards clinical translation; illustrate RGD-based radiotracers that have been investigated in clinical trials; and discuss the other applications of RGD radiotracers aside from tumor detection.

Keywords: Arg-Gly-Asp (RGD), integrin αvβ3, molecular imaging, radionuclide therapy, radiotracer, tumor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 20 November, 2013
Page: [1487 - 1505]
Pages: 19
DOI: 10.2174/1566524013666131111115347
Price: $65

Article Metrics

PDF: 32